IP Library › Granted Patent US 10,117,861
Granted Patent B2
US 10,117,861 · App. 15/784,376 · Granted Nov 6, 2018

Phenyl derivative

Inventors: Atsushi Naganawa (Osaka, JP); Kensuke Kusumi (Osaka, JP); Kazuhiro Otsuki (Osaka, JP); Tetsuya Sekiguchi (Osaka, JP); Akito Kakuuchi (Osaka, JP); Koji Shinozaki (Osaka, JP); Hiroshi Yamamoto (Osaka, JP); Shigeyuki Nonaka (Osaka, JP)
Assignee: ONO PHARMACEUTICAL CO., LTD.
A61K31/445A61K31/397A61K31/40A61K31/453A61K31/454A61K31/4523A61K31/4545C07D205/04C07D207/12C07D207/16C07D211/48C07D211/52C07D401/12C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,861
App. No.
15/784,376
Granted
Nov 6, 2018
Kind
B2
Abstract

The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P 2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P 2 -mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.

Claims (4)

1. A method of treating a S1P2-mediated disease, comprising administering to a mammal an effective amount of 2-{4-[3-(4-fluorophenoxy)-5-{[(4-hydroxy-4-isobutyl-1-piperidinyl)carbonyl]amino}phenoxy]phenyl}-2-methylpropanoic acid, or a salt thereof.

2. The method according to claim 1 , wherein the S1P2-mediated disease is a disease resulting from vascular constriction, fibrosis, peripheral arterial occlusive disease, hepatitis, hepatic cirrhosis, or hepatic failure.

3. The method according to claim 2 , wherein the disease resulting from vascular constriction is cerebral vasospastic disease, cardiac vasospastic disease, coronary vasospastic disease, hypertension, pulmonary hypertension, myocardial infarction, angina, arrhythmia, portal hypertension, varix, or ischemia-reperfusion injury.

4. The method according to claim 2 , wherein the fibrosis is pulmonary fibrosis, hepatic fibrosis, kidney fibrosis, myocardial fibrosis, or skin fibrosis.

Priority Claims (1)
JP 2011-213987 · Sep 29, 2011 · national
Continuity (4)
Division 15089690 · Apr 4, 2016
Division 14592100 · Jan 8, 2015
Continuation 14347178
Related Publication 20180042908A1 · Feb 15, 2018